Science Daily: Pharmacology News
APRIL 16, 2025
According to new research next-generation DNA sequencing (NGS) -- the same technology which is powering the development of tailor-made medicines, cancer diagnostics, infectious disease tracking, and gene research -- could become a prime target for hackers.
Drugs.com
APRIL 15, 2025
TUESDAY, April 15, 2025 — A newly approved antibiotic to treat urinary tract infections may also help fight drug-resistant gonorrhea, a new study shows. The medication, called gepotidacin, sold under the brand name Blujepa, could become the.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Covalent Modifiers
APRIL 13, 2025
Tyler M. McCullough, Vishakha Choudhary, David L. Akey, Meredith A. Skiba, Steffen M. Bernard, Jeffrey D. Kittendorf, Jennifer J. Schmidt, David H. Sherman, and Janet L. Smith ACS Catalysis 2024 14 (16), 12551-12563 DOI: 10.1021/acscatal.4c03637 Emerging antibiotic resistance requires continual improvement in the arsenal of antimicrobial drugs, especially the critical macrolide antibiotics.
BioPharma Drive: Drug Pricing
APRIL 14, 2025
The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
New Drug Approvals
APRIL 11, 2025
Fitusiran 1711.0g/mol, C 78 H 139 N 11 O 30 FDA APPROVED 3/28/2025, Qfitlia , To prevent or reduce the frequency of bleeding episodes in hemophilia A or B Press Release CAS 1499251-18-1 EX-A12034 DA-53206 N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Science Daily: Pharmacology News
APRIL 11, 2025
Astronomers are investigating the longest and most energetic bursts of X-rays seen from a newly awakened black hole. Watching this strange behavior unfold in real time offers a unique opportunity to learn more about these powerful events and the mysterious behavior of massive black holes.
Drugs.com
APRIL 14, 2025
MONDAY, April 14, 2025 -- When officials in Wisconsin's largest city asked the U.S. Centers for Disease Control and Prevention (CDC) for help dealing with high levels of lead in city schools, the answer wasn't what they expected. The CDC said no.
BioPharma Drive: Drug Pricing
APRIL 11, 2025
The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin Makary was sworn in.
Drug Patent Watch
APRIL 14, 2025
"Compliance in Generic Drug Development: A Critical Component of Success As the generic drug industry continues to grow, ensuring compliance with regulatory requirements has become a top priority for pharmaceutical companies. At DrugPatentWatch, we've seen firsthand the importance of staying on top of regulatory changes and maintaining a robust compliance program.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Covalent Modifiers
APRIL 13, 2025
Waldmann H, Zhang R, liu J, Gasper R, Janning P. ChemRxiv. 2025 doi:10.26434/chemrxiv-2025-70x40. [link] For targeted covalent protein modification at low reactivity aspartates and glutamates, new methods are in high demand. Inspired by the HaloTag technology we have developed a new technique which employs a reaction between chloroalkane-functionalised ligands and a specific glutamate residue.
Science Daily: Pharmacology News
APRIL 14, 2025
Microplastics and the much smaller nanoplastics enter the human body in various ways, for example through food or the air we breathe. A large proportion is excreted, but a certain amount remains in organs, blood and other body fluids. Scientists have now been able to develop a method for detecting and quantifying nanoplastics in transparent body fluids and determining their chemical composition.
Drugs.com
APRIL 11, 2025
FRIDAY, April 11, 2025 -- The U.S. Centers for Disease Control and Prevention (CDC) now recommends extra measles protection for people traveling to areas with active outbreaks in the United States, CBS News reported.In an April 8 letter, the CDC.
BioPharma Drive: Drug Pricing
APRIL 16, 2025
Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also show promising — albeit unproven — signs of efficacy.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
FDA Law Blog: Biosimilars
APRIL 13, 2025
By Sarah Wicks & Dara Katcher Levy FDAs Office of Prescription Drug Promotion (OPDP) issued its second Untitled Letter of 2025 to Taiho Oncology (Taiho) for a healthcare provider branded website for its drug LYTGOBI (futibatinib). This letter, dated March 21, 2025, cites Taihos false or misleading representations about the benefits of the drug, which is considered misbranding under the Federal Food, Drug, and Cosmetic Act.
Codon
APRIL 17, 2025
In the early 2010s, Chilean plant ecologists Ernesto Gianoli and Fernando Currasco-Urra spotted what looked like a peculiar tree stem in the rainforest. On closer inspection, they realized it was a vine, Boquila trifoliolata , imitating a nearby tree’s leaves — closely matching their size, shape, and vein patterns. After further study, Gianoli and Carrasco-Urra discovered that this aptly named “Chameleon Vine” could mimic all sorts of plants, or even multiple different pl
Science Daily: Pharmacology News
APRIL 16, 2025
Drugs like Ozempic, other blood sugar-reducing medications, may stave off dementia.
Drugs.com
APRIL 11, 2025
FRIDAY, April 11, 2025 -- How children respond to movement could provide an early means of detecting autism, a new study says.Children with autism are known to prefer watching repetitive movements over random movements, researchers said.Using.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
BioPharma Drive: Drug Pricing
APRIL 14, 2025
As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S. tariffs on their products.
Perficient: Drug Development
APRIL 17, 2025
Creating operable content in pharmacies that accommodates the diverse needs and preferences of all users is critical for accessibility. The Universal Design principle of Flexibility in Use supports operable content by enabling multiple methods of interaction and adaptation. Pharmacies can use this principle to ensure that everyone, regardless of physical, cognitive, or sensory abilities, can engage comfortably with their services.
The Premier Consulting Blog
APRIL 13, 2025
On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ 1] Instead, within 3-5 years, the expectation will be to leverage an integrated safety assessment approach, combining information from a comprehensive battery of New Approach Methodologies (NAM).
Science Daily: Pharmacology News
APRIL 11, 2025
A team of researchers reported the first direct observation of a surprising quantum phenomenon predicted over half a century ago known as a superradiant phase transition, which occurs when two groups of quantum particles begin to fluctuate in a coordinated, collective way without any external trigger, forming a new state of matter.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
APRIL 14, 2025
MONDAY, April 14, 2025 -- Worried about taking the ADHD meds youve been prescribed because they might harm your heart health?Theres no need to fret, according to a new evidence review.ADHD medications generally have just a small effect on a per.
BioPharma Drive: Drug Pricing
APRIL 16, 2025
The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, also discussed the Texas measles outbreak.
Perficient: Drug Development
APRIL 17, 2025
The principle of Low Physical Effort is central to creating operable content and environments that are accessible to all customers. In pharmacies, this Universal Design principle ensures that services, tools, and spaces require minimal physical strain, allowing individuals with mobility limitations, chronic conditions, or temporary injuries to engage comfortably.
Drug Target Review
APRIL 14, 2025
The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs. This is where Brian Finrows expertise comes in.
Science Daily: Pharmacology News
APRIL 11, 2025
Using electrodes in a fluid form, researchers have developed a battery that can take any shape. This soft and conformable battery can be integrated into future technology in a completely new way.
Drugs.com
APRIL 14, 2025
MONDAY, April 14, 2025 -- The U.S. Food and Drug Administration announced it is shifting away from animal testing in the development of monoclonal antibody therapies and other drugs, favoring more effective, human-relevant methods.The new strategy.
BioPharma Drive: Drug Pricing
APRIL 17, 2025
The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, swelling Lilly's market value by more than $100 billion.
LifeSciVC
APRIL 17, 2025
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Drug discovery and development is a long, and often fraught, journey it typically takes more than a decade to progress from idea to approved drug, and less than 10% of drugs that enter the clinic succeed in achieving commercialization. Creating new drugs for patients is certainly not for the faint of heart.
Expert insights. Personalized for you.
343 
Let's personalize your content